Alloy Therapeutics
PrivateLast Round
Series E
Apr 15, 2026
Est. Valuation
$1B
Total Funding Raised
$185.75M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Alloy Therapeutics operates in Healthcare & Life Sciences and is based in Waltham, Massachusetts. Its latest recorded funding round was a Series E round in April 2026.
Alloy Therapeutics is a biotechnology ecosystem company that provides AI-powered platforms, scientific expertise, and integrated services to support drug discovery and development across multiple therapeutic modalities.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Subscription SaaS, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Alloy Therapeutics Comparables
Compare Alloy Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Harbour BioMed | 83% | |
| OmniAb Inc. | 83% | |
| AbCellera Biologics Inc. | 82% |
For institutional investors. Book with your work email.
Alloy Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Apr 15, 2026 | ||||
| Series D | Oct 3, 2022 | ||||
| Series C | Apr 2, 2021 | ||||
| Series B | May 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Alloy Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Echo Investment Capital | Series E |
| Thiel Capital | Series E, Series D |
| Gaingels | Series C, Series E |
| Founders Fund | Series C, Series E, Series D |
| Presight Capital | Series E, Series D, Series C |
| JIC Venture Growth Investments | Series E |
| Mubadala Capital | Series E, Series C, Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 23, 2026
Formation of a 'Scientific AI' business unit announced.
- Oct 23, 2026
Job posting reveals Vigilance, a national security division.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresAug 26, 2026
Alloy Therapeutics, Inc. hires Dalton Makrush as Associate Director, Protein Analytics, where he develops methods and workflows to accelerate antibody developability for partner programs.
For institutional investors. Book with your work email.
Alloy Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Alloy Therapeutics's valuation, stock price, and market status.
Is Alloy Therapeutics a public or private company?
Alloy Therapeutics is a private company.
What is the current stock price of Alloy Therapeutics?
Alloy Therapeutics is a private company, so its shares have no public market price. Caplight tracks Alloy Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Alloy Therapeutics worth (valuation)?
Alloy Therapeutics's valuation is estimated at $1.0B based on funding round data.
Can I buy Alloy Therapeutics stock?
Alloy Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Alloy Therapeutics's last funding round?
Alloy Therapeutics's most recent funding round was Series E on April 15, 2026.
Who are the main investors in Alloy Therapeutics?
Key investors in Alloy Therapeutics include Echo Investment Capital, Presight Capital, JIC Venture Growth Investments, 8VC, Mubadala Investment Company.
Will Alloy Therapeutics IPO soon?
No public IPO plans have been announced for Alloy Therapeutics.
How can I track Alloy Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Alloy Therapeutics's shares on secondary markets.